| Previous Close | 8.47 |
| Open | 8.23 |
| Bid | 8.06 x 0 |
| Ask | 8.14 x 0 |
| Day's Range | 8.23 - 8.23 |
| 52 Week Range | 5.60 - 14.08 |
| Volume | 150 |
| Avg. Volume | 2,765 |
| Market Cap | 220.016M |
| Beta (5Y Monthly) | -0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.68 |
| Earnings Date | Mar. 29, 2018 - Apr. 02, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
FENC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Encourages Investors to Contact the Firm
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Fennec securities between February 11, 2020 and August 10, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/fenc. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges that Defendants failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company’s sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/fenc or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Fennec you have until November 2, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com
- Newsfile
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 2, 2020 - FENC
New York, New York--(Newsfile Corp. - September 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fennec Pharmaceuticals Inc. ("Fennec") (NASDAQ: FENC) between February 11, 2020 and August 10, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the the United States District Court for the Middle District of North Carolina. To ...
- ACCESSWIRE
LAWSUITS FILED AGAINST FE, FENC and NNOX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
NEW YORK, NY / ACCESSWIRE / September 21, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.
